Last reviewed · How we verify
CAR-T cells targeting EpCAM
At a glance
| Generic name | CAR-T cells targeting EpCAM |
|---|---|
| Sponsor | Jian-Kun Hu |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- IMC001 for Clinical Research on Advanced Digestive System Malignancies (PHASE1)
- Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART) (PHASE1)
- Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer (NA)
- Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer (NA)
- A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAR-T cells targeting EpCAM CI brief — competitive landscape report
- CAR-T cells targeting EpCAM updates RSS · CI watch RSS
- Jian-Kun Hu portfolio CI